Researchers from the University of Jyväskylä in Finland have found that continued treatment of muscle wasting with a soluble growth factor receptor protein, produced at the University of Helsinki, improved survival in a pre-clinical cancer mouse model without affecting the tumour size.
This effect was not found when the mice were treated with the recombinant protein only prophylactically before cancer.
The results are published in the leading muscle research journal Journal of Cachexia, Sarcopenia and Muscle.
“These findings, together with a few earlier rodent studies as well as a rather large body of epidemiological evidence in humans, have led to suggestions of a possible causal link between the preservation of muscle mass and improved survival. It can be speculated that the preservation of some specific, vital muscles, such as the major respiratory muscles, may be especially important for this effect,” says PhD student Tuuli Nissinen and the Academy of Finland Research Fellow and group leader Juha Hulmi.
“However,” they continue, “our results cannot rule out some muscle-independent effects of our protein. It seems that circulating pro-inflammatory cytokines, physical activity, or hepatic and splenic physiology, which were all altered in cancer, may not be determining factors for improved survival with the soluble growth factor receptor, more specifically soluble activin receptor 2B.”
The study was conducted in the Faculty of Sport and Health Sciences at the University of Jyväskylä in collaboration with researchers in Helsinki and Torino.
The study was funded by the Academy of Finland, the Cancer Society of Finland, and the Jenny and Antti Wihuri Foundation.
Source: University of Jyväskylä